Stage IIIC Melanoma, AREA[OverallStatus], Open or Pending: 16 Clinical Trials, Page 1 of 2

1 2

Include Studies Not Open or Pending

4

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma

Condition(s):Clinical Stage IV Cutaneous Melanoma AJCC v8; IL13RA2 Positive; Metastatic Melanoma; Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Melanoma; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell CarcinomaLast Updated:March 22, 2024Recruiting

5

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Condition(s):Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Hormone Receptor-Positive Breast Carcinoma; Locally Advanced Cutaneous Melanoma; Metastatic Acral Lentiginous Melanoma; Metastatic Conjunctival Melanoma; Metastatic Cutaneous Melanoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Mucosal Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Acral Lentiginous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Mucosal Melanoma; Refractory HER2-Negative Breast Carcinoma; Unresectable Acral Lentiginous Melanoma; Unresectable Cutaneous Melanoma; Unresectable Mucosal MelanomaLast Updated:January 25, 2024Recruiting

1 2

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.